[FG] Cippà Pietro & Schaub Stefan

Our research group is committed to advancing both the scientific understanding and clinical management of kidney transplantation. Our primary goal is to improve long-term outcomes for transplant recipients by integrating cutting-edge research with patient-centered care. A central focus of our work is the monitoring of kidney allografts after transplantation, aiming to detect early signs of rejection and graft dysfunction. Through the identification and validation of reliable biomarkers, we seek to enhance diagnostic accuracy and enable timely, individualized therapeutic interventions.

Personalized immunosuppression is a key pillar of our approach. By tailoring treatment regimens to the unique immunological profiles of patients, we strive to optimize efficacy while minimizing adverse effects. Our research also delves deeply into HLA biology and the complex interplay of HLA and non-HLA immune responses in graft injury. Particular attention is given to chronic antibody-mediated rejection, a persistent challenge in transplantation medicine. In this area, we are actively involved in clinical studies that evaluate novel therapeutic strategies aimed at controlling immune-mediated damage.

Our translational efforts focus on developing innovative interventions to modulate the immune system, with the long-term vision of achieving immunological tolerance and reducing the need for lifelong immunosuppression. By bridging laboratory discoveries with clinical application, we aim to uncover the mechanisms driving allograft dysfunction and translate these insights into improved patient outcomes.